Trial Profile
A Multi-center, Randomized, Double-Blinded Study of the Efficacy and Safety of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction (OBD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Dec 2019
Price :
$35
*
At a glance
- Drugs Lubiprostone (Primary)
- Indications Constipation
- Focus Registrational; Therapeutic Use
- Sponsors Sucampo Pharmaceuticals
- 28 Aug 2017 Results of post-hoc pooled analysis of this and other 5 studies published in the Digestive Diseases and Sciences.
- 11 May 2013 Results presented at the 32nd Annual Scientific Meeting of the American Pain Society.
- 01 May 2013 New trial record